Q3 2023 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
Financial review
Conclusions
Financial performance
Immunology
LNA043-ANGPTL3 agonist
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
NCT04864392 ONWARDS (CLNA043A12202)
Knee osteoarthritis
Phase 2
Indication
Phase
Patients
550
Primary
Outcome
Measures
Arms
Intervention
Change from baseline in the cartilage thickness of the medial compartment of
the knee as assessed by imaging
LNA043 injection to the knee with dosing regimen A
LNA043 injection to the knee with dosing regimen B
LNA043 injection to the knee with dosing regimen C
LNA043 injection to the knee with dosing regimen D
Placebo injection to the knee
Patients with Symptomatic knee osteoarthritis
Target
Patients
Readout
Milestone(s)
Primary 2024
Publication
TBD
References
Abbreviations
Other
59 Investor Relations | Q3 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation